Clinuvel receives IND status
Afamelanotide granted IND status by US FDA
- 29 January, 2009 13:17
- Comments
Melbourne’s Clinuvel has received investigational new drug (IND) status for its photoprotective drug afamelanotide from the US FDA.
The ruling will allow the company to begin clinical trials in the US. It received orphan drug designation from the FDA in July last year.
Afamelanotide is currently in Phase III trials for the treatment of erythropoietic protoporphyria (EPP) in Europe and Australia, amongst several other trials in UV-related skin disorders.
Books
-
Molecular & Cell Biology for Dummies
-
Molecular Forensics
-
Fluorescence Applications in Biotechnology and Life Sciences
-
Introduction to Statistics for Forensic Scientists
-
The Scientific American a Day in the Life of Your Brain
-
An Introduction to Molecular Biotechnology - Molecular Fundamentals, Methods and Applications in Modern Biotechnology
-
Proteins - Structure and Function
-
Dictionary of DNA and Genome Technology 2E
-
Writing Scientific Research Articles - Strategy and Steps
Comments
Post new comment